Laddar...
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
BACKGROUND: As long-term treatment with antitumour necrosis factor (TNF) drugs becomes accepted practice, the risk assessment requires an understanding of anti-TNF long-term safety. Registry safety data in rheumatoid arthritis (RA) are available, but these patients may not be monitored as closely as...
Sparad:
| Huvudupphovsmän: | , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BMJ Group
2013
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3595151/ https://ncbi.nlm.nih.gov/pubmed/22562972 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2011-201244 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|